Human HLA‑DR PE‑conjugated Antibody

Name: Human HLA‑DR PE‑conjugated Antibody
Brand: R&D Systems
SKU: FAB4869P
Price: 439 USD
Availability: InStock

R&D Systems | Catalog # FAB4869P

Submit a review

Citations (18)

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Spectra Viewer
Flow Cytometry
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Flow Cytometry

Cited:

Flow Cytometry

Label

Phycoerythrin (Excitation = 488 nm, Emission = 565-605 nm)

Antibody Source

Monoclonal Mouse IgG₁ Clone # L203

View all HLA-DR Primary Antibodies »

Product Specifications

Immunogen

RPMI 8866 human lymphoblastoid cells
Accession # P01903

Specificity

Detects human HLA‑DR.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁

Scientific Data Images for Human HLA‑DR PE‑conjugated Antibody

Detection of HLA‑DR in Human Blood Lymphocytes by Flow Cytometry.

Human peripheral blood lymphocytes were stained with (A) Mouse Anti-Human HLA-DR PE-conjugated Monoclonal Antibody (Catalog # FAB4869P) or (B) isotype control antibody (Catalog # IC002P) and Mouse anti-Human CD19 APC-conjugated Monoclonal Antibody (Catalog # FAB4867A). View our protocol for Staining Membrane-associated Proteins.

Detection of Human HLA-DR by Flow Cytometry

Costimulatory profile of mature DCs generated with a 3-day protocol. (A) Shown is the expression of specific surface molecules detected on DCs by flow cytometry in a representative patient sample generated with cocktail RP. (B) Comparison of the expression intensity of the costimulatory molecules CD80 and CD86 and the coinhibitory molecules CD273 and CD274 between HCs and AML patients. The mean fluorescence (MFI) of at least three individual experiments of HC and AML patients were compared using the different maturation cocktails C, CP, R, and RP. Image collected and cropped by CiteAb from the following publication (https://translational-medicine.biomedcentral.com/articles/10.1186/1479-…), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human HLA‑DR PE‑conjugated Antibody

Application

Recommended Usage

Flow Cytometry

10 µL/10⁶ cells
Sample: Human peripheral blood lymphocytes

Spectra Viewer

Plan Your Experiments

Use our spectra viewer to interactively plan your experiments, assessing multiplexing options. View the excitation and emission spectra for our fluorescent dye range and other commonly used dyes.

Spectra Viewer

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
Spillover Popups - Visualize the spectra of individual fluorochromes
Antigen Density Selector - Match fluorochrome brightness with antigen density

Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

Supplied in a saline solution containing BSA and Sodium Azide.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

12 months from date of receipt, 2 to 8 °C as supplied.

Background: HLA-DR

HLA-DR is a transmembrane human major histocompatibility complex 2 (MHC II) family member and consists of a 34 kDa (alpha) subunit and one of several 28 kDa (beta) subunits. HLA-DR is expressed primarily by B cells and dendritic cells (DC), in which it binds peptides derived from internalized and processed antigenic proteins. It presents these peptides on the cell surface for recognition by the T cell receptor on CD4⁺ T cells. This interaction is central to antigen specificity in the adaptive immune response. HLA-DR alleles, polymorphisms, and aberrant expression are linked to a variety of diseases including autoimmunity and cancer.